Zimbabwe has turned down a substantial American healthcare agreement worth $367m (£272m) spanning five years due to the United States' demand for sensitive biological samples.
This move was revealed following a official document dated December was leaked, indicating that Head of State Emmerson Mnangagwa deemed the arrangement was "skewed".
A government representative has since stated that the US was requesting biological samples for scientific study and commercial purposes but refused to share the resulting advantages from any future vaccines.
"We are forced to start the challenging and unfortunate task of winding down our health assistance in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont publicly.
The US Embassy noted the US had provided more than $1.9bn as health assistance to Zimbabwe during the past two decades.
A doctors' association in Zimbabwe has called for more negotiations to reach a deal agreeable to both sides so the nation's vital HIV treatment initiative can be sustained.
Broader Background
Zimbabwe's decision follows a comparable case in neighbouring Kenya, where a high court halted a related health funding agreement following legal challenges were filed about the security of citizens' medical information.
Since resuming office last year, US President Donald Trump has reduced overseas assistance and closed the US Agency for International Development (USAID).
The agency had administered assistance for the American government, but Trump stated its expenditure was "inefficient" and his administration was pursuing direct bilateral deals to enhance openness and accountability.
According to statements, Sixteen African countries have to date signed these new agreements, constituting over $18.3bn in new funding.
Details of the Rejected Agreement
The money for Zimbabwe would have funded "tackling HIV/Aids, TB, malaria, healthcare for mothers and children, and preparing for epidemics".
"It is our view this cooperation would have delivered significant benefits for Zimbabwean communities, particularly the 1.2 million presently on antiretroviral therapy via American-funded programmes," Tremont added.
However, official spokesman Nick Mangwana argued the arrangement was "asymmetrical".
"Zimbabwe was being asked to surrender its genetic material and health information over an extended period, without any corresponding guarantee of access to any medical innovations – such as new medicines or tests – that might be developed from that provided information," his statement read.
"In essence, our country would provide the raw materials for medical research without any certainty that the end products would be available to our citizens if a future health crisis arise."
National Interest and Global Health
He also pointed out that the American exit from the World Health Organization (WHO) and its pursuit of bilateral deals were undermining frameworks already set up via the global health agency.
Mangwana cited its Pathogen Access and Benefit Sharing system created to manage potential global health emergencies.
"This system is designed to guarantee that when a nation provides its samples, the resulting advantages – including medicines and cures – are distributed fairly, not commercialised exclusively by those with the resources to develop them."
Zimbabwe's reservations over the US deal "must not be interpreted as opposition to America," Mangwana stressed.
"We welcome further discussions with our American counterparts on how future collaboration might be designed in a way that honours the sovereignty and dignity of each country."
Medical Community Response
A leading public health body said it understood the government's concerns, but recommended that talks need to persist since much of the nation's Aids initiatives relied on external financing.
"Where technical issues arise, including those relating to data governance or agreement terms, these can often be addressed through detailed discussion and mutually agreed protections," it said.
The halted deal emphasises the continuing tensions between accepting much-needed international aid and protecting national sovereignty in an increasingly data-driven world.